Panobacumab (KBPA101) strongly binds to 18 of 20 clinical O11 isolates, functional avidity of KBPA101 to O11 LPS determined by inhibition ELISA is 5.81×107 M-1± 2.8×107 M-1[1].
Panobacumab (KBPA101) (0.0001-100 ng/mL; 2 h) specifically mediates complement-dependent opsonophagocytosis of P. aeruginosa serotype O11 with an IC50 of 0.16 ng/mL[1].
Panobacumab (KBPA101) (0.1-10 ng/mL) shows direct complement-dependent killing of P. aeruginosa serotype O11 cells in a dose-dependent manner[1].
Panobacumab (KBPA101) (1-4 mg/kg; i.v.; once) protects mice from systemic infection with P. aeruginosa serotype O11 in a murine burn wound model[1].
Panobacumab (KBPA101) (0.005-0.4 mg/kg; i.v.; once) protects mice from local lung infection with P. aeruginosa serotype O11 in an acute lung infection model[1].
References:
[1]. Horn MP, et al. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother. 2010 Jun;54(6):2338-44.